Trial Profile

Anlotinib Combined With Docetaxel Versus Docetaxel for Platinum-based Therapy Treated Advanced NSCLC: a Multicentre, Randomised Explorative Trial

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Docetaxel
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms ACWDVDFPTAN; ALTER-L016

13 Sep 2022 Updated results presented at the 47th European Society for Medical Oncology Congress
13 Sep 2022 Results of pooled analysis of two studies (ALTER-L016: NCT03726736; ALTER-L018: NCT03624309) assessing efficacy and safety anlotinib plus docetaxel in the treatment of non-small cell lung cancer, presented at the 47th European Society for Medical Oncology Congress.
09 Aug 2022 Results of pooled analysis (n=73) assessing the efficacy and safety of anlotinib plus docetaxel in advanced NSCLC patients (pts) who had been pre-treated with ICIs presented at the 2022 World Conference on Lung Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com